USC Epstein Family Alzheimer's Therapeutic Research Institute — Accelerating Alzheimer's Prevention
0+
Years of Research
0+
Clinical Trials
76+
Research Sites
2490+
Participants Enrolled
14900+
Patients Screened for Trials
"The biggest word that I can use right now is the word hope. I just feel very, very lucky, and I don't want to go back to that dark place."
Lisa
ATRI Advocate
"Being part of this study opened my eyes to how much people don't know. We need to work together to slow down and one day eliminate this disease."
Carol
ATRI Collaborative Trial Participant
"My wake up call was learning I had a high likelihood for AD. I want everyone to know the importance of participating in trials. It's the only way we can delay and prevent this disease."
Nancy
ATRI Collaborative Trial Participant
Paul Aisen, MD
Founding Director
Learn About the Rigorous Science Behind Our Trials and Why It Differentiates Us.
"Our focus is uncompromising trials and unprecedented global collaboration with both academia and industry. We want solutions where early detection can be simple, affordable and accessible."
For more than a decade, ATRI has pioneered the most rigorous approach to Alzheimer's clinical trials. Under Dr. Aisen's leadership, the institute has built an unmatched infrastructure for designing and executing large-scale multicenter trials that are advancing the field toward prevention.
Dr. Aisen’s scientific philosophy centers on precision, collaboration, and the belief that Alzheimer’s disease can be prevented through early intervention and innovative trial design.
Read More About Our Approach →OUR MISSION AND VISION
TO PREVENT AND EFFECTIVELY TREAT ALZHEIMER'S DISEASE AND RELATED DEMENTIAS
ATRI’s collaborations are behind the latest FDA-approved drugs which slow the Alzheimer’s Disease progression. Additionally, our work has played an important role in validating the impacts of emerging biomarkers — the new blood tests — to screen for early disease detection. As a global leader in trial research, we are constantly striving to build smarter studies by analyzing not only results, but also examining our completed protocols, adapting future protocols, and sharing all data with other researchers.
We’re also focusing on new frontiers: exploring links among Alzheimer’s Disease and conditions such as Parkinson’s, Dementia with Lewy Bodies, and Down syndrome.
We now know which toxic proteins start these diseases, and we believe we have the tools to fix it.
We now know which toxic proteins start these diseases, and we believe we have the tools to fix it.
The Alzheimer's Clinical Trials Consortium
ATRI is the nexus for groundbreaking clinical trials. Led by USC, Harvard and The Mayo Clinic, our specialty is designing and conducting intervention research. We foster collaboration and drive innovation globally for Alzheimer’s Disease research.
Learn More